TB-500 Reconstitution Chart (Every Vial Size)

Mathematical Formulas and Volumetric Calculations for TB-500 Reconstitution

Accurate peptide reconstitution requires establishing an explicit ratio between the mass of the lyophilized cake and the volume of liquid diluent introduced. In laboratory settings, calculating target concentration (expressed in milligrams per milliliter, mg/mL) ensures reproducible sampling during assay preparation. Researchers should utilize the primary equation: Concentration (mg/mL) = Mass of Lyophilized Peptide (mg) / Volume of Diluent Added (mL). To determine the mass present within a specific aliquot, multiply the sample volume by the established concentration.

To illustrate this mathematical framework, consider two standard laboratory scenarios using lyophilized vials from our catalog of research peptides. First, reconstituting a 5mg vial of TB-500 with 2.0 mL of bacteriostatic water yields a final concentration of 2.5 mg/mL (5 mg ÷ 2.0 mL). At this concentration, a standard 0.1 mL volumetric draw contains exactly 0.25 mg (250 mcg) of active peptide. Second, reconstituting a higher-yield TB-500 Thymosin Beta-4 10mg vial with 2.5 mL of diluent yields a final concentration of 4.0 mg/mL (10 mg ÷ 2.5 mL). In this configuration, a 0.1 mL volumetric draw yields 0.40 mg (400 mcg) of compound. Researchers looking to automate these calculations for varying assay parameters can utilize our interactive reconstitution calculator.

Comprehensive TB-500 Reconstitution Reference Table

The following standardized matrix outlines concentration outcomes across standard laboratory vial sizes (2mg, 5mg, and 10mg) and conventional diluent volumes. Use these benchmark metrics to achieve target milligram-per-milliliter yields without manual recalculation during high-throughput experimentation.

| Vial Mass (mg) | Diluent Volume (mL) | Resulting Concentration (mg/mL) | Peptide Mass per 0.1 mL Draw | Peptide Mass per 0.05 mL Draw | |---|---|---|---|---| | 2.0 mg | 1.0 mL | 2.0 mg/mL | 0.20 mg (200 mcg) | 0.10 mg (100 mcg) | | 2.0 mg | 2.0 mL | 1.0 mg/mL | 0.10 mg (100 mcg) | 0.05 mg (50 mcg) | | 5.0 mg | 1.0 mL | 5.0 mg/mL | 0.50 mg (500 mcg) | 0.25 mg (250 mcg) | | 5.0 mg | 2.0 mL | 2.5 mg/mL | 0.25 mg (250 mcg) | 0.125 mg (125 mcg) | | 5.0 mg | 2.5 mL | 2.0 mg/mL | 0.20 mg (200 mcg) | 0.10 mg (100 mcg) | | 10.0 mg | 1.0 mL | 10.0 mg/mL | 1.00 mg (1000 mcg) | 0.50 mg (500 mcg) | | 10.0 mg | 2.0 mL | 5.0 mg/mL | 0.50 mg (500 mcg) | 0.25 mg (250 mcg) | | 10.0 mg | 2.5 mL | 4.0 mg/mL | 0.40 mg (400 mcg) | 0.20 mg (200 mcg) | | 10.0 mg | 5.0 mL | 2.0 mg/mL | 0.20 mg (200 mcg) | 0.10 mg (100 mcg) |

This volumetric scale guarantees precise delivery across variable experimental designs. Researchers requiring custom concentrations for automated liquid-handling systems or specialized cell culture models should refer to our peptide research library for advanced reconstitutive models and solvent compatibility guidelines.

Molecular Profile and Preclinical Investigation of TB-500 (Thymosin Beta-4)

TB-500 is a synthetic peptide derivative corresponding to the active domain of naturally occurring Thymosin Beta-4 (Tβ4), a 43-amino-acid protein encoded by the TMSB4X gene. Classified primarily as a regeneration peptide, TB-500 plays a pivotal biophysical role by sequestering monomeric G-actin (globular actin). Preclinical studies suggest that by forming a 1:1 complex with G-actin, TB-500 inhibits spontaneous actin polymerization while maintaining a dynamic pool of monomers required for rapid cytoskeletal remodeling during cellular distress.

In vitro data and animal models indicate that TB-500 is actively investigated for promoting cell migration, blood-vessel formation (angiogenesis), and structural flexibility during soft-tissue and muscle-fiber recovery. By upregulated expression of matrix metalloproteinases and downregulating focal adhesion kinase signaling, the compound facilitates endothelial cell locomotion into injured tissue matrices. Furthermore, preclinical observations demonstrate that TB-500 supports extracellular matrix turnover, reducing collagenous scar formation and promoting organized myofibrillar alignment in damaged skeletal and cardiac tissues.

Diluent Selection Criteria: Bacteriostatic Water vs. Sterile Saline

Selecting an appropriate solvent is vital for maintaining peptide stability and preventing microbial growth during multi-dose laboratory sampling. The primary diluent recommended for reconstituting TB-500 is Bacteriostatic Water for Injection, which contains 0.9% benzyl alcohol (9 mg/mL) as a preservative agent. Benzyl alcohol acts as a bacteriostatic inhibitor, preventing bacterial replication and enabling multi-use sampling over an extended storage window when kept under refrigeration.

Alternatively, 0.9% Sodium Chloride (Sterile Normal Saline) or pure Sterile Water for Injection (SWFI) may be utilized for single-use, immediate-assay applications. However, lacking preservative agents, aqueous solutions prepared with SWFI or saline must be utilized immediately or discarded to prevent contamination. When designing multi-day rodent studies or extended cellular assays, researchers should utilize bacteriostatic diluents to preserve peptide integrity and prevent degradation induced by bacterial enzymes. Detailed handling protocols for various diluents can be reviewed in our bacteriostatic water guidelines.

Step-by-Step Aseptic Reconstitution Protocol

To preserve the structural integrity of the 43-amino-acid sequence and prevent accidental contamination, reconstitution must occur within a laminar flow hood or a sterile laboratory cabinet following standard operating procedures. Begin by retrieving the lyophilized vial and diluent from cold storage, allowing both components to reach ambient temperature (20°C to 25°C) to prevent thermal shock to the peptide matrix.

Sanitize the rubber septum of both the peptide vial and diluent container using an alcohol swab saturated with 70% isopropyl alcohol. Using a sterile, single-use syringe fitted with a high-gauge needle, draw the calculated volume of diluent (e.g., 2.5 mL). Insert the needle through the center of the TB-500 vial septum at a 45-degree angle, aiming the stream along the internal glass wall rather than directly onto the lyophilized cake. Allow the vacuum pressure within the vial to draw the liquid smoothly. Once injected, gently swirl the vial in a circular motion until the cake fully dissolves into a clear, colorless liquid. Never shake or agitate the vial vigorously, as mechanical shear stress can denature fragile peptide bonds.

Comparative Analysis: TB-500 and Parallel Regeneration Compounds

In preclinical tissue-repair research, TB-500 is frequently evaluated alongside or in combination with other specialized tissue-regenerative agents to observe synergistic pathways. For instance, BPC-157 is a pentadecapeptide investigated for its pronounced gastric stability and focal upregulation of growth factor receptors (such as VEGFR2), whereas TB-500 primarily operates via systemic actin sequestration and endothelial cell migration. While BPC-157 acts locally on ligamentous insertions and mucosal linings, TB-500 demonstrates broader systemic mobility due to its lower molecular binding affinity to local extracellular matrices.

Another relevant comparator in extracellular matrix remodeling assays is GHK-Cu, a tripeptide-copper complex extensively studied for modulating gene expression involved in collagen synthesis and skin remodeling. Additionally, researchers examining systemic repair mechanisms occasionally combine TB-500 with secretagogues like CJC-1295 to evaluate downstream anabolic growth factor activity during muscle-fiber regeneration. Understanding these mechanistic differences allows researchers to structure comparative study designs effectively.

Storage Parameters, Degradation Pathways, and Solution Stability

Lyophilized TB-500 exhibits high thermodynamic stability when stored in desiccated cold conditions. Unreconstituted vials kept at -20°C remain stable for up to 24 months, while short-term storage at 2°C to 8°C is acceptable for up to 90 days prior to solvent introduction. Chemical degradation pathways for lyophilized peptides primarily involve hydrolysis and oxidation at sensitive methionine or cysteine residues, which are minimized by maintaining low temperatures and protective nitrogen atmospheres during lyophilization.

Once reconstituted with bacteriostatic water, liquid TB-500 must be stored continuously at 2°C to 8°C (36°F to 46°F) and used within 28 days. Avoid repeated freeze-thaw cycles of reconstituted liquid solutions, as ice crystal formation disrupts tertiary peptide conformation and causes rapid activity loss. If long-term storage of a reconstituted solution is unavoidable, aliquot the solution into single-use polypropylene micro-centrifuge tubes and store at -80°C. Further scientific guidelines regarding temperature sensitivity are available in our technical report on peptide storage and handling.

Analytical Verification: HPLC, Mass Spectrometry, and Quality Assurance

To ensure high experimental fidelity, PX1 Research subjects every lot of TB-500 to rigorous analytical verification before distribution. Purity is validated using High-Performance Liquid Chromatography (HPLC), guaranteeing that active peptide content exceeds 99.0%. Mass Spectrometry (MS) is simultaneously performed to verify exact identity, matching molecular weight against theoretical values to confirm the absence of truncated sequences or synthesis impurities.

Furthermore, all product batches undergo quantitative bacterial endotoxin testing (LAL assay) to maintain levels safely below stringent research thresholds (<0.05 EU/mg). Products are manufactured within ISO 17025 accredited facilities operating under strict GMP compliance in the USA. Every shipment includes access to a lot-specific third-party Certificate of Analysis (COA) detailing full analytical spectra. Orders are processed with same-day shipping (Monday through Friday) operating out of dual fulfillment hubs in California and Arizona. University laboratories and corporate R&D divisions seeking volume purchasing agreements can review our bulk lab purchasing program.